<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00562237</url>
  </required_header>
  <id_info>
    <org_study_id>S205.1.001</org_study_id>
    <secondary_id>2007-000876-17</secondary_id>
    <nct_id>NCT00562237</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Vaccine</brief_title>
  <official_title>Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Surface Antigen Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solvay Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Solvay Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several combinations of H5N1 antigen concentrations and aluminium-hydroxide adjuvant
      concentrations will be tested for their safety and capacity to induce a specific immune
      response.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This trial discontinued on 20 JUN 2008 because the interim immunogenicity results do not
    justify these formulations as pandemic vaccine candidates
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">September 2008</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemagglutination inhibition titers</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CHMP criteria</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virus neutralization</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HA antibody level kinetics</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>S205 placebo</intervention_name>
    <description>2 i.m. injections per subject (0.5 mL each)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>S205 10ugHA</intervention_name>
    <description>2 i.m. injections per subject (0.5 mL each)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>S205 30ugHA</intervention_name>
    <description>2 i.m. injections per subject (0.5 mL each)</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>S205 10ugHA+500ugAlOH</intervention_name>
    <description>2 i.m. injections per subject (0.5 mL each)</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>S205 30ugHA+500ugAlOH</intervention_name>
    <description>2 i.m. injections per subject (0.5 mL each)</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>S205 10ugHA+1250ugAlOH</intervention_name>
    <description>2 i.m. injections per subject (0.5 mL each)</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>S205 30ugHA+1250ugAlOH</intervention_name>
    <description>2 i.m. injections per subject (0.5 mL each)</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  being healthy and ≥ 18 and ≤ 49 years of age

          -  willing and able to give informed consent

        Exclusion Criteria:

          -  having participated in an influenza H5 vaccine trial in the past

          -  known to be allergic to any constituent of the vaccine

          -  serious adverse reactions to previous (influenza) vaccination

          -  currently participating in another clinical trial or having participated in any
             clinical trial in the month preceding the start of the study

          -  using medication that influences the immune system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Director Solvay</last_name>
    <role>Study Director</role>
    <affiliation>Solvay Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 21</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 22</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 23</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 12</name>
      <address>
        <city>Goch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 10</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 11</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2007</study_first_submitted>
  <study_first_submitted_qc>November 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2007</study_first_posted>
  <last_update_submitted>October 24, 2008</last_update_submitted>
  <last_update_submitted_qc>October 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2008</last_update_posted>
  <responsible_party>
    <name_title>Joost Melis</name_title>
    <organization>Solvay Pharmaceuticals</organization>
  </responsible_party>
  <keyword>immunogenicity</keyword>
  <keyword>safety</keyword>
  <keyword>adjuvanted pandemic vaccine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

